Oral delivery of biologics using drug-device combinations
Orally administered devices could enable the systemic uptake of biologic therapeutics by engineering around the physiological barriers present in the gastrointestinal (GI) tract. Such devices aim to shield cargo from degradative enzymes and increase the diffusion rate of medication through the GI mu...
| Main Authors: | , , , |
|---|---|
| Other Authors: | |
| Format: | Article |
| Language: | English |
| Published: |
Elsevier BV
2020
|
| Online Access: | https://hdl.handle.net/1721.1/128617 |
| _version_ | 1826206688344014848 |
|---|---|
| author | Caffarel Salvador, Ester Abramson, Alex Langer, Robert S Traverso, Giovanni |
| author2 | Massachusetts Institute of Technology. Institute for Medical Engineering & Science |
| author_facet | Massachusetts Institute of Technology. Institute for Medical Engineering & Science Caffarel Salvador, Ester Abramson, Alex Langer, Robert S Traverso, Giovanni |
| author_sort | Caffarel Salvador, Ester |
| collection | MIT |
| description | Orally administered devices could enable the systemic uptake of biologic therapeutics by engineering around the physiological barriers present in the gastrointestinal (GI) tract. Such devices aim to shield cargo from degradative enzymes and increase the diffusion rate of medication through the GI mucosa. In order to achieve clinical relevance, these designs must significantly increase systemic drug bioavailability, deliver a clinically relevant dose and remain safe when taken frequently. Such an achievement stands to reduce our dependence on needle injections, potentially increasing patient adherence and reducing needle-associated complications. Here we discuss the physical and chemical constraints imposed by the GI organs and use these to develop a set of boundary conditions on oral device designs for the delivery of macromolecules. We critically examine how device size affects the rate of intestinal obstruction and hinders the loading capacity of poorly soluble protein drugs. We then discuss how current orally administered devices could solve the problem of tissue permeation and conclude that these physical methods stand to provide an efficacious set of alternatives to the classic hypodermic needle. ©2017 Elsevier Ltd |
| first_indexed | 2024-09-23T13:37:01Z |
| format | Article |
| id | mit-1721.1/128617 |
| institution | Massachusetts Institute of Technology |
| language | English |
| last_indexed | 2024-09-23T13:37:01Z |
| publishDate | 2020 |
| publisher | Elsevier BV |
| record_format | dspace |
| spelling | mit-1721.1/1286172022-10-01T16:04:59Z Oral delivery of biologics using drug-device combinations Caffarel Salvador, Ester Abramson, Alex Langer, Robert S Traverso, Giovanni Massachusetts Institute of Technology. Institute for Medical Engineering & Science Massachusetts Institute of Technology. Department of Chemical Engineering Koch Institute for Integrative Cancer Research at MIT Orally administered devices could enable the systemic uptake of biologic therapeutics by engineering around the physiological barriers present in the gastrointestinal (GI) tract. Such devices aim to shield cargo from degradative enzymes and increase the diffusion rate of medication through the GI mucosa. In order to achieve clinical relevance, these designs must significantly increase systemic drug bioavailability, deliver a clinically relevant dose and remain safe when taken frequently. Such an achievement stands to reduce our dependence on needle injections, potentially increasing patient adherence and reducing needle-associated complications. Here we discuss the physical and chemical constraints imposed by the GI organs and use these to develop a set of boundary conditions on oral device designs for the delivery of macromolecules. We critically examine how device size affects the rate of intestinal obstruction and hinders the loading capacity of poorly soluble protein drugs. We then discuss how current orally administered devices could solve the problem of tissue permeation and conclude that these physical methods stand to provide an efficacious set of alternatives to the classic hypodermic needle. ©2017 Elsevier Ltd National Institutes of Health (EB-000244) 2020-11-23T22:55:52Z 2020-11-23T22:55:52Z 2017-08 2019-09-06T19:15:36Z Article http://purl.org/eprint/type/JournalArticle 1471-4973 https://hdl.handle.net/1721.1/128617 Caffarel-Salvador, Ester et al., "Oral delivery of biologics using drug-device combinations." Current Opinion in Pharmacology 36 (October 2017): 8-13 doi. 10.1016/j.coph.2017.07.003 ©2017 Authors en https://dx.doi.org/10.1016/J.COPH.2017.07.003 Current Opinion in Pharmacology Creative Commons Attribution-NonCommercial-NoDerivs License http://creativecommons.org/licenses/by-nc-nd/4.0/ application/pdf Elsevier BV PMC |
| spellingShingle | Caffarel Salvador, Ester Abramson, Alex Langer, Robert S Traverso, Giovanni Oral delivery of biologics using drug-device combinations |
| title | Oral delivery of biologics using drug-device combinations |
| title_full | Oral delivery of biologics using drug-device combinations |
| title_fullStr | Oral delivery of biologics using drug-device combinations |
| title_full_unstemmed | Oral delivery of biologics using drug-device combinations |
| title_short | Oral delivery of biologics using drug-device combinations |
| title_sort | oral delivery of biologics using drug device combinations |
| url | https://hdl.handle.net/1721.1/128617 |
| work_keys_str_mv | AT caffarelsalvadorester oraldeliveryofbiologicsusingdrugdevicecombinations AT abramsonalex oraldeliveryofbiologicsusingdrugdevicecombinations AT langerroberts oraldeliveryofbiologicsusingdrugdevicecombinations AT traversogiovanni oraldeliveryofbiologicsusingdrugdevicecombinations |